PharmaSens and SiBionics Collaborate on Innovative Diabetes Patch Pump Development

PharmaSens and SiBionics Collaboration for Diabetes Management



PharmaSens AG, a pioneer in next-generation insulin patch pump technology based in Switzerland, has announced a strategic collaboration with SiBionics, a leader in continuous glucose monitoring (CGM). This partnership marks a significant advancement in diabetes care, focusing on the development of the niia™ signature, an innovative all-in-one wearable patch pump that seamlessly integrates insulin delivery with real-time glucose sensing capabilities.

The initiative aims to alleviate the daily challenges faced by individuals managing diabetes by simplifying therapy through an advanced, user-friendly device. According to Marcel Both, the CEO of PharmaSens, this collaboration is a monumental step towards creating a fully integrated and discreet insulin-therapy system. He expressed confidence in the partnership, stating, “SiBionics' expertise in sensor technology perfectly complements our innovative platform.”

The Vision Behind the Collaboration


By merging their respective strengths, PharmaSens and SiBionics are set to deliver a product that not only enhances convenience for users but also elevates the quality of diabetes management. The niia™ signature device will leverage PharmaSens' patented platform alongside SiBionics' state-of-the-art biosensor technology, integrating engineering and development resources from both entities to launch a comprehensive patch pump solution.

PharmaSens has a rich history in diabetes technology, boasting a portfolio filled with innovative medical devices and insulin pumps. Their collaborative efforts with SiBionics will further propel the evolution of diabetes management solutions, expected to reduce the daily burdens faced by insulin users. This collaboration emphasizes the necessity of minimal invasiveness and seamless user experience in diabetes care.

About the Companies


PharmaSens AG is dedicated to simplifying diabetes management through innovative insulin delivery systems. With a skilled team that has been pivotal in advancing insulin pump generations, PharmaSens is committed to broadening access to effective diabetes technology. The company’s expertise stems from years of comprehensive research, resulting in a portfolio of patented products designed to enhance the lives of diabetes patients worldwide.

On the other hand, SiBionics, founded in 2015, operates with a mission to transform healthcare technology. With headquarters in Shenzhen, China, and Irvine, California, SiBionics specializes in the research and development of medical devices, and is committed to improving health insights for patients through intelligent biosensors and user-friendly technology. Their workforce, comprised of over 500 professionals, includes many research scientists from prestigious institutions in both China and the U.S.

The Future of Diabetes Care


As both companies embark on this promising venture, the niia™ signature is positioned to reshape how individuals approach diabetes management. By offering an integrated system that combines glucose monitoring and insulin delivery, the goal is to reduce the complexities of diabetes therapy and enhance the quality of life for patients.

As this collaboration progresses, the industry eagerly anticipates the launch of the niia™ signature patch pump, which promises to set a new standard in diabetes technology. For more detailed information, you can visit PharmaSens and SiBionics.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.